Abstract: The present invention establishes a molecular therapy for glycogen storage disease type Ia. The present invention provides an oligonucleotide of 15-30 bases comprising a nucleotide sequence complementary to die cDNA of G6PC gene with c.648G>T mutation, wherein the oligonucleotide comprises a sequence complementary to a region comprising any site between the 82nd to the 92nd nucleotide from the 5? end of exon 5 of the G6PC gene with c.648C>T mutation, a pharmacologically acceptable salt or solvate thereof. Also provided is a pharmaceutical drug comprising the oligonucleotide, a pharmacologically acceptable salt or solvate thereof (e.g., therapeutic drug for glycogen storage disease type Ia).

Abstract: A sensor includes a complex-transfer-function calculator that calculates a complex transfer function from received signals, a reflection-coefficient calculator that calculates a reflection coefficient using a complex transfer function when an object to be detected is arranged at one of L positions and an ideal complex transfer function which is a theoretical value for the position at which the object to be detected is arranged, various normalizers that calculate a normalized reflection coefficient by normalizing the reflection coefficient, a reflection-coefficient interpolator that calculates an interpolated reflection coefficient by interpolation calculation of the reflection coefficient using the normalized reflection coefficient for each coordinates used in position estimation of the object to be detected, and a position estimator that corrects the position estimation, using a steering vector and the interpolated reflection coefficient that are determined based on the position of each of the transmitting a

Abstract: In a structure of a disconnect plug of an electric vehicle, a plug bracket is raised from an inside of a battery unit to an inside of a bulge formed on a floor panel under rear seats for preventing a submarine motion of a passenger. In addition, a disconnect plug is detachably attached to a front face of a plug bracket, and an opening for accessing to the disconnect plug is formed on a front wall of the bulge. Further, a cover for covering the opening capable of being opened and closed is provided on a trim beneath a front face of a seat cushion of the rear seats.

Abstract: A standard calibration solution includes water, a non-alcoholic solvent that is mixed with water, and a steroid hormone, and a content of the non-alcoholic solvent is 10% by volume or more and 50% by volume or less. The standard calibration solution is used for quantitative measurement using a mass spectrometry device.

Abstract: A light emitting apparatus having a first light emitting region and a second light emitting region, the second light emitting region including the first light emitting region and having a larger area than that of the first light emitting region, a first light emitting element being included in the first light emitting region, a second light emitting element being not included in the first light emitting region but included in the second light emitting region, the light emitting apparatus having a first emission mode where only the first light emitting region emits light and a second emission mode where the second light emitting region emits light, the light emitting apparatus includes a control unit configured to, in the second emission mode, control a difference between an amount of light emitted by the first light emitting element and an amount of light emitted by the second light emitting element.

Abstract: There are provided a terminal device, a data management device, a management system, a processing method, a data management method, a management method, and a non-transitory computer-readable medium storing a program that are capable of improving reliability. A terminal device is connected to a network together with other terminal devices, retains a blockchain formed by linking data generated by the respective terminal devices or a hash value of the data as blocks together with the other terminal devices, and adds, when a new terminal device is to be added to the network, new data generated by the new terminal device or a hash value of the new data to the blockchain together with the other terminal devices.

Abstract: The present disclosure provides an organic light-emitting element including a first electrode, an organic compound layer, and a second electrode, wherein the organic compound layer includes a charge transport layer, and the charge transport layer includes a first charge transport layer, a second charge transport layer, and a third charge transport layer in this order, and the first charge transport layer, the second charge transport layer, and the third charge transport layer satisfy Formulas (1) and (2) below: ?1>?2>?3??(1) d1+d2<d3??(2) in Formula (1), ?1, ?2, and ?3 are charge mobilities of the first to third charge transport layers, and in Formula (2), d1, d2, and d3 are layer thicknesses of the first to third charge transport layers.

Abstract: A composition contains an organic compound and an anthracene compound different from the organic compound, the anthracene compound having a hydrogen atom at at least one of positions 9 and 10, in which the concentration of the anthracene compound is 100 ppm or less. Additionally, a long-lived organic light-emitting device includes an organic compound layer containing a reduced concentration of the anthracene compound.

Abstract: A composition contains an organic compound and an anthracene compound different from the organic compound, the anthracene compound having a hydrogen atom at at least one of positions 9 and 10, in which the concentration of the anthracene compound is 100 ppm or less. Additionally, a long-lived organic light-emitting device includes an organic compound layer containing a reduced concentration of the anthracene compound.

Abstract: A growth analysis system (1) according to an example aspect of the present disclosure, comprising a correlation deriving unit (60) comprising a first neural network that uses growth condition information as input data to output contained component information as output data. The correlation deriving unit (60) causes the first neural network to learn by repeatedly performing deep learning using, as training data, the growth condition information and the contained component information indicating the component contained in the organisms that are actually grown in accordance with the growth condition.

Abstract: The present invention provides a conjugate of an oligonucleotide having a nucleic acid sequence expected to have a pharmacological effect in hepatic parenchymal cells with a biantennary GalNAc unit, or a pharmaceutically acceptable salt thereof, and a medicament or the like containing the same as an active component.

Abstract: A counting system 100 of the present invention includes an image acquisition means 121 for acquiring a captured image obtained by capturing an imaging area that is a partial area of an object area, a detection means 122 for detecting a person existing in the imaging area from the captured image, a measurement means 123 for, on the basis of a detection result of the person, measuring a staying time that is a period of time in which the person stays in the imaging area, and a calculation means 124 for, on the basis of the detection result of the person and the staying time, calculating the number of persons existing in the object area.

Abstract: Provided are a device and a method for rapidly and simply detecting endotoxin without using an expensive reagent. The endotoxin detection device includes: a region containing an electrolyte solution; a partitioning member that partitions the region into two compartments such that the two compartments are in communication via a nanopore; a first electrode that is disposed in a first compartment; a second electrode that is disposed in a second compartment and is electrically connected to the first electrode; an electrolyte solution flow generating means that causes electrolyte solution in the first compartment to move to the second compartment via the nanopore; an application means that applies voltage between the first electrode and the second electrode; and a monitoring means that monitors current.

Abstract: An organic light-emitting device includes, on an insulating layer, a first lower electrode, an upper electrode, and an organic compound layer disposed between the first lower electrode and the upper electrode, wherein the organic compound layer includes a first light-emitting layer, a second light-emitting layer disposed between the first light-emitting layer and the upper electrode, and a first organic compound layer disposed between the first light-emitting layer and the second light-emitting layer, the first organic compound layer includes a second organic compound layer containing an alkali metal, and a third organic compound layer disposed between the second organic compound layer and the upper electrode and containing a compound having a lowest unoccupied molecular orbital level energy of -5.0 eV or less, and an orthogonal projection of the first organic compound layer onto the insulating layer is smaller than an orthogonal projection of the first light-emitting layer onto the insulating layer.

Abstract: The present invention provides a compound having excellent histone acetyl transferase inhibitory activity against EP300 and/or CREBBP, or a pharmacologically acceptable salt thereof. The compound is represented by the following formula (1) or a pharmacologically acceptable salt thereof: wherein ring Q1, ring Q2, R1, R2, R3 and R4 respectively have the same meanings as defined in the specification.

Abstract: Provided are a device and a method for rapidly and simply detecting endotoxin without using an expensive reagent. The endotoxin detection device includes: a region containing an electrolyte solution; a partitioning member that partitions the region into two compartments such that the two compartments are in communication via a nanopore; a first electrode that is disposed in a first compartment; a second electrode that is disposed in a second compartment and is electrically connected to the first electrode; an electrolyte solution flow generating means that causes electrolyte solution in the first compartment to move to the second compartment via the nanopore; an application means that applies voltage between the first electrode and the second electrode; and a monitoring means that monitors current.

Abstract: A composition that includes: a homo-N-trans (HNT) iridium complex having an iridium atom, and a first ligand, a second ligand, and a third ligand that are bonded to the iridium atom, the second ligand having the same structure as the first ligand, the third ligand having a different structure from the first and second ligands; and an isomer of the iridium complex, the isomer having an iridium atom, a fourth ligand, a fifth ligand, and the third ligand, the fourth ligand being a ligand represented by the same rational formula as that of the first ligand, and the fifth ligand being a ligand represented by the same rational formula as that of the second ligand. The composition ratio of the isomer relative to a total of the iridium complex and the isomer is 1.5% or more.

Abstract: A composition that contains an iridium complex and an isomer of the iridium complex, in which the amount of the isomer of the iridium complex is decreased. The iridium complex is a homo-N-trans (HNT) iridium complex having an iridium atom, and a first ligand, a second ligand, and a third ligand that are bonded to the iridium atom. The isomer has an iridium atom, a fourth ligand, a fifth ligand, and the third ligand. The composition ratio of the isomer relative to a total of the iridium complex and the isomer is 1.0% or less.

Abstract: An easily operable dimming device includes a dimming element operable to control the transmittance thereof for light, and a first notification device operable to make a notification of a piece of information on a change in transmittance of the dimming section.

Abstract: The present invention provides a compound having excellent histone acetyl transferase inhibitory activity against EP300 and/or CREBBP, or a pharmacologically acceptable salt thereof. The compound is represented by the following formula (1) or a pharmacologically acceptable salt thereof: wherein ring Q1, ring Q2, R1, R2, R3 and R4 respectively have the same meanings as defined in the specification.